JPS6447715A - Improver for ovulation inductive pregnant genital physiological dysfunction - Google Patents
Improver for ovulation inductive pregnant genital physiological dysfunctionInfo
- Publication number
- JPS6447715A JPS6447715A JP20191987A JP20191987A JPS6447715A JP S6447715 A JPS6447715 A JP S6447715A JP 20191987 A JP20191987 A JP 20191987A JP 20191987 A JP20191987 A JP 20191987A JP S6447715 A JPS6447715 A JP S6447715A
- Authority
- JP
- Japan
- Prior art keywords
- improver
- tryptophan
- genital
- pregnant
- ovulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
PURPOSE:To obtain the titled pharmaceutical, containing L-tryptophan as an active ingredient, capable of inducing an increase in the number of human or animal ovulation without side effects, such as pregnant genital physiological dysfunction, especially abnormality by external stimulation, e.g. fetal cacogenesis. CONSTITUTION:An improver obtained by containing L-tryptophan which is one kind of essential amino acids contained in normal foods as an active ingredient. In use, the L-tryptophan can be used alone and in combination with other active ingredients. The improver is administered by any of methods for oral and parenteral administration. Intravenous, intramuscular and subcutaneous injections, etc., are cited as the parenteral administration. Continuous administration once a day for several days is effective in administering the improver, preferably in the anestrous or anaphrodisiac period once a day for 5-7 days. The dose thereof is 25-500mg/kg in the case of oral administration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20191987A JPS6447715A (en) | 1987-08-14 | 1987-08-14 | Improver for ovulation inductive pregnant genital physiological dysfunction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20191987A JPS6447715A (en) | 1987-08-14 | 1987-08-14 | Improver for ovulation inductive pregnant genital physiological dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6447715A true JPS6447715A (en) | 1989-02-22 |
Family
ID=16448974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP20191987A Pending JPS6447715A (en) | 1987-08-14 | 1987-08-14 | Improver for ovulation inductive pregnant genital physiological dysfunction |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6447715A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4874821A (en) * | 1987-07-31 | 1989-10-17 | Enichem Elastomeri S.P.A. | Block copolymer and process for preparing it |
-
1987
- 1987-08-14 JP JP20191987A patent/JPS6447715A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4874821A (en) * | 1987-07-31 | 1989-10-17 | Enichem Elastomeri S.P.A. | Block copolymer and process for preparing it |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yu et al. | Role of endogenous interferon-γ on the enhancement of splenic NK cell activity by electroacupuncture stimulation in mice | |
| ATE94393T1 (en) | DOSE FORM FOR ORAL ADMINISTRATION OF HYPOGLYCAEMIC GLIPICIDE. | |
| NO171145C (en) | PROCEDURE FOR PREPARING A FAT EMULSION WITH A HYDROPHOBIC MEDICINE | |
| JPS57212114A (en) | Capsule containing allergen activator and preparation therefor | |
| KR930702022A (en) | Treatment or prevention of type 1 diabetes by oral administration of insulin | |
| KR940018089A (en) | Prevention and treatment for radiation damage of internal tissue | |
| NZ229518A (en) | Pharmaceutical dosage form for the medication of fish: method of administration and (prophylactic) treatment | |
| MY109309A (en) | Improvements in or relating to somatostatins | |
| Memon et al. | In vivo effects of interferon-alpha and interferon-gamma on lipolysis and ketogenesis | |
| RU95101385A (en) | Products containing g-csf and tnf-binding protein | |
| Yehuda et al. | Thermoregulatory and locomotor effects of DSIP: paradoxical interaction with d-amphetamine | |
| EP0414772A4 (en) | Method for treating acne | |
| KR910005858A (en) | Fatty acid therapy | |
| MY105798A (en) | Treatment of leukocyte dysfunction with gm-csf. | |
| SHALABY et al. | In vivo augmentation of natural killer activity by combined treatment with recombinant gamma interferon and interleukin-2 | |
| IL161665A0 (en) | Method of administering a thymosin alpha 1 peptide | |
| JPS6447715A (en) | Improver for ovulation inductive pregnant genital physiological dysfunction | |
| MY106603A (en) | Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon | |
| Lao et al. | Electroacupuncture reduces morphine-induced emesis in ferrets: a pilot study | |
| EP0106812A2 (en) | Pharmaceutical composition containing a fibrinolytic agent and a diffusion factor, useful for the treatment of the myocardium infarction | |
| KR930003913A (en) | Methods and pharmaceutical compositions for enhancing the antitussive effect of dextromethorphan | |
| JPS6416721A (en) | Antioxidant | |
| ATE141510T1 (en) | MEDICINAL PRODUCTS CONTAINING CD14 | |
| EG17992A (en) | Preparation of a medicament for arthritis and theumatism | |
| Biskind | The relation of nutritional deficiency to impaired libido and potency in the male |